Gustav Christensen is chairman of Morphic Therapeutic, a public biotech company. He was president and chief executive officer of Dyax Corp (NASDAQ: DYAX) from January 1, 2009 until it was acquired by Shire for $6.4 billion in January 2016. He joined Dyax in early 2007 as executive vice president and chief business officer. Gustav began his caree...
Roles at Generation Bio